Soleno Therapeutics Securities Class Action Reminder
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 15 2026
0mins
Source: PRnewswire
- Lawsuit Background: Hagens Berman reminds investors of the pending securities class action against Soleno Therapeutics (NASDAQ:SLNO), with a lead plaintiff deadline of May 5, 2026, for those who purchased shares between March 26 and November 4, 2025.
- Safety Risk Allegations: The lawsuit alleges that Soleno misrepresented the safety and commercial viability of its flagship product, VYKAT™ XR (DCCR), for treating Prader-Willi syndrome, leading to significant investor losses due to concealed risks.
- Stock Price Plunge: On November 4, 2025, Soleno reported Q3 results, admitting disruptions in DCCR's launch trajectory, resulting in a 27% stock price drop in one day, indicating severe market disappointment regarding the company's future.
- Whistleblower Program: Hagens Berman encourages individuals with non-public information to consider the SEC Whistleblower program, which offers rewards of up to 30% of any successful recovery, thereby aiding the investigation into Soleno's practices.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
